Antitrust merger review
Antitrust merger review in Healthcare & Life Sciences is one of the most litigated regulatory intersections in the United States right now, with the U.S. Federal Trade Commission and the U.S. Department of Justice Antitrust Division both pressing harder on hospital consolidations, pharmaceutical acquisitions, and health insurer tie-ups than at any point in the past decade. The European Commission's Directorate-General for Competition has added a separate layer of scrutiny for cross-border deals involving EU-market biologics and medical device manufacturers. Compliance teams at targets and acquirers alike are stress-testing deal timelines against second-request probability before signing.
Watch
- FTC's 2023 Merger Guidelines: how courts are actually applying them to hospital deals
- Second-request rates on pharma acquisitions above $500M are climbing; budget timelines accordingly
- EC's Article 22 referral mechanism pulling sub-threshold health tech deals into Brussels review
- DOJ Antitrust Division remedy posture: divestitures vs. behavioral remedies in recent PBM cases
- State attorneys general coordinating parallel challenges after federal clearance in provider mergers
Recent material activity in Healthcare & Life Sciences
Active monitoring in place across Healthcare & Life Sciences. Material developments related to antitrust merger review will appear here as they are published.